← golden set
TMO
THERMO FISHER SCIENTIFIC INC.Healthcareanswer key
| field | SEC value | XBRL concept | printed on |
|---|---|---|---|
| Total revenue | $44.6B | RevenueFromContractWithCustomerExcludingAssessedTax | Total revenues |
| Operating income | $7.7B | OperatingIncomeLoss | Operating income |
| Net income attributable to the company | $6.7B | NetIncomeLoss | Net income attributable to Thermo Fisher Scientific Inc. |
| Diluted EPS | $17.74 | EarningsPerShareDiluted | Diluted |
| Cash and cash equivalents | $9.9B | CashAndCashEquivalentsAtCarryingValue | Cash and cash equivalents |
| Total assets | $110.3B | Assets | Total assets · Total liabilities, redeemable noncontrolling interest and equity |
| Total liabilities | - | not reported | not in this filing's XBRL |
| Total shareholders' equity attributable to the company | $53.4B | StockholdersEquity | Total Thermo Fisher Scientific Inc. shareholders’ equity |
| Net cash from operating activities | $7.8B | NetCashProvidedByUsedInOperatingActivities | Net cash provided by operating activities |
| Net cash from investing activities | -$4.0B | NetCashProvidedByUsedInInvestingActivities | Net cash used in investing activities |
| Net cash from financing activities | $1.8B | NetCashProvidedByUsedInFinancingActivities | Net cash provided by/(used in) financing activities |
Income statement
table #17 · score 51 vs 27.3 runner-up · in millions| Year Ended | |||
| December 31, | December 31, | December 31, | |
| (In millions except per share amounts) | 2025 | 2024 | 2023 |
| Revenues | |||
| Product revenues | 25,965 | 25,034 | 25,243 |
| Service revenues | 18,592 | 17,845 | 17,614 |
| Total revenues | 44,556 | 42,879 | 42,857 |
| Costs and operating expenses: | |||
| Cost of product revenues | 13,405 | 12,523 | 13,168 |
| Cost of service revenues | 12,913 | 12,654 | 12,589 |
| Selling, general and administrative expenses | 8,732 | 8,595 | 8,445 |
| Research and development expenses | 1,397 | 1,390 | 1,337 |
| Restructuring and other costs | 362 | 379 | 459 |
| Total costs and operating expenses | 36,810 | 35,542 | 35,998 |
| Operating income | 7,746 | 7,337 | 6,859 |
| Interest income | 993 | 1,078 | 879 |
| Interest expense | (1,419) | (1,390) | (1,375) |
| Other income/(expense) | (12) | 12 | (65) |
| Income before income taxes | 7,308 | 7,037 | 6,298 |
| Benefit from/(provision for) income taxes | (547) | (657) | (284) |
| Equity in earnings/(losses) of unconsolidated entities | (41) | (42) | (59) |
| Net income | 6,721 | 6,338 | 5,955 |
| Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest | 17 | 3 | (40) |
| Net income attributable to Thermo Fisher Scientific Inc. | 6,704 | 6,335 | 5,995 |
| Earnings per share attributable to Thermo Fisher Scientific Inc. | |||
| Basic | 17.77 | 16.58 | 15.52 |
| Diluted | 17.74 | 16.53 | 15.45 |
| Weighted average shares | |||
| Basic | 377 | 382 | 386 |
| Diluted | 378 | 383 | 388 |
Balance sheet
table #16 · score 53 vs 23.8 runner-up · in millions| December 31, | December 31, | |
| (In millions except share and per share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 9,852 | 4,009 |
| Short-term investments | 253 | 1,561 |
| Accounts receivable, less allowances of $147 and $173 | 8,900 | 8,191 |
| Inventories | 5,425 | 4,978 |
| Contract assets, net | 1,666 | 1,435 |
| Other current assets | 2,612 | 1,964 |
| Total current assets | 28,707 | 22,137 |
| Property, plant and equipment, net | 10,565 | 9,306 |
| Acquisition-related intangible assets, net | 15,838 | 15,533 |
| Other assets | 5,871 | 4,492 |
| Goodwill | 49,362 | 45,853 |
| Total assets | 110,343 | 97,321 |
| Liabilities, redeemable noncontrolling interest and equity | ||
| Current liabilities: | ||
| Short-term obligations and current maturities of long-term obligations | 3,533 | 2,214 |
| Accounts payable | 3,622 | 3,079 |
| Accrued payroll and employee benefits | 1,995 | 1,988 |
| Contract liabilities | 2,710 | 2,852 |
| Other accrued expenses | 3,329 | 3,199 |
| Total current liabilities | 15,189 | 13,332 |
| Deferred income taxes | 1,493 | 1,268 |
| Other long-term liabilities | 4,273 | 3,989 |
| Long-term obligations | 35,852 | 29,061 |
| Commitments and contingencies (Note 5) | ||
| Redeemable noncontrolling interest | 122 | 120 |
| Equity: | ||
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | - | - |
| Common stock, $1 par value, 1,200,000,000 shares authorized; 445,160,301 and 443,841,240 shares issued | 445 | 444 |
| Capital in excess of par value | 18,563 | 17,962 |
| Retained earnings | 59,156 | 53,102 |
| Treasury stock at cost, 68,938,831 and 63,066,906 shares | (22,309) | (19,226) |
| Accumulated other comprehensive income/(loss) | (2,448) | (2,697) |
| Total Thermo Fisher Scientific Inc. shareholders’ equity | 53,407 | 49,584 |
| Noncontrolling interests | 7 | (33) |
| Total equity | 53,415 | 49,551 |
| Total liabilities, redeemable noncontrolling interest and equity | 110,343 | 97,321 |
Cash flow statement
table #19 · score 53.5 vs 17.5 runner-up · in millions| Year Ended | |||
| December 31, | December 31, | December 31, | |
| (In millions) | 2025 | 2024 | 2023 |
| Operating activities | |||
| Net income | 6,721 | 6,338 | 5,955 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation of property, plant and equipment | 1,050 | 1,156 | 1,068 |
| Amortization of acquisition-related intangible assets | 1,730 | 1,952 | 2,338 |
| Change in deferred income taxes | (639) | (1,209) | (1,300) |
| Stock-based compensation | 310 | 301 | 278 |
| Other net non-cash expenses | 455 | 508 | 604 |
| Changes in assets and liabilities, excluding the effects of acquisitions: | |||
| Accounts receivable | (426) | (171) | (43) |
| Inventories | (74) | (27) | 598 |
| Contract assets/liabilities | (375) | (162) | 252 |
| Accounts payable | 421 | 212 | (500) |
| Contributions to retirement plans | (42) | (45) | (42) |
| Other | (1,312) | (186) | (802) |
| Net cash provided by operating activities | 7,818 | 8,667 | 8,406 |
| Investing activities | |||
| Purchases of property, plant and equipment | (1,525) | (1,400) | (1,479) |
| Proceeds from sale of property, plant and equipment | 44 | 57 | 87 |
| Proceeds from cross-currency interest rate swap interest settlements | 268 | 252 | 70 |
| Acquisitions, net of cash acquired | (4,037) | (3,132) | (3,660) |
| Purchases of investments | (383) | (3,396) | (208) |
| Proceeds from sales and maturities of investments | 1,565 | 1,770 | 15 |
| Other investing activities, net | 21 | 8 | 33 |
| Net cash used in investing activities | (4,047) | (5,841) | (5,142) |
| Financing activities | |||
| Net proceeds from issuance of debt | 7,759 | 1,204 | 5,942 |
| Repayment of debt | (2,412) | (3,607) | (5,782) |
| Proceeds from issuance of commercial paper | 1,095 | - | 1,620 |
| Repayments of commercial paper | (1,095) | - | (1,935) |
| Purchases of company common stock | (3,000) | (4,000) | (3,000) |
| Dividends paid | (636) | (583) | (523) |
| Other financing activities, net | 90 | 195 | 56 |
| Net cash provided by/(used in) financing activities | 1,801 | (6,792) | (3,622) |
| Exchange rate effect on cash | 267 | (91) | (82) |
| Increase/(decrease) in cash, cash equivalents and restricted cash | 5,839 | (4,057) | (440) |
| Cash, cash equivalents and restricted cash at beginning of year | 4,040 | 8,097 | 8,537 |
| Cash, cash equivalents and restricted cash at end of year | 9,879 | 4,040 | 8,097 |